STAT-Diagnostica, a Barcelona, Spain-based provider of a Near Patient Testing diagnostic system, closed a €17m (approxiamtely $22.1m) Series B financing round.
The round was led by new investor Kurma Life Sciences Partners, with participation from new investors Idinvest, Boehringer Ingelheim Venture Fund, and Caixa Capital Risc, as well as existing investors Ysios Capital and Axis.
The company intends to use the funds to complete development of its system and clinical validation of its first products.
Founded in 2010 by Jordi Carrera, CEO, STAT-Diagnostica develops Near Patient Testing systems that simplify and reduce time to results for the diagnosis of certain medical conditions. The first clinical applications will be directed at infectious disease detection, antibiotic resistance determination and detection of biomarkers in critically ill patients.
FinSMEs
06/05/2013